-
1
-
-
79952232216
-
Global cancer statistics
-
PID: 21296855
-
Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
-
2
-
-
79954610137
-
Colorectal cancer in India: controversies, enigmas and primary prevention
-
PID: 21222189, COI: 1:STN:280:DC%2BC3MvivVyktg%3D%3D
-
Mohandas K. Colorectal cancer in India: controversies, enigmas and primary prevention. Indian J Gastroenterol. 2011;30:3–6.
-
(2011)
Indian J Gastroenterol
, vol.30
, pp. 3-6
-
-
Mohandas, K.1
-
3
-
-
2642541396
-
-
(eds), IARC Press, Lyon:
-
Ferlay J, Bray F, Pisani P, Parkin DM, editors. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. CancerBase No. 5, Version 2.0. Lyon: IARC Press; 2004.
-
(2004)
GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. CancerBase No. 5, Version 2.0
-
-
Ferlay, J.1
Bray, F.2
Pisani, P.3
Parkin, D.M.4
-
4
-
-
21344438905
-
Colorectal cancer: (neo-) adjuvant treatments in colorectal cancer
-
Arnold D, Schmoll HJ. Colorectal cancer: (neo-) adjuvant treatments in colorectal cancer. Ann Oncol. 2005;16:133–40.
-
(2005)
Ann Oncol
, vol.16
, pp. 133-140
-
-
Arnold, D.1
Schmoll, H.J.2
-
5
-
-
67749122122
-
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
-
PID: 19629070, COI: 1:CAS:528:DC%2BD1MXovFylsrg%3D
-
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 550-562
-
-
Engelman, J.A.1
-
6
-
-
20444374445
-
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
-
PID: 15950905, COI: 1:CAS:528:DC%2BD2MXlslCgsrY%3D
-
Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561–73.
-
(2005)
Cancer Cell
, vol.7
, pp. 561-573
-
-
Samuels, Y.1
Diaz, L.A.2
Schmidt-Kittler, O.3
-
7
-
-
33645812174
-
Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies
-
PID: 16619509, COI: 1:CAS:528:DC%2BD28XktFWms7c%3D
-
Oikonomou E, Pintzas A. Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. Anticancer Res. 2006;26:1077–84.
-
(2006)
Anticancer Res
, vol.26
, pp. 1077-1084
-
-
Oikonomou, E.1
Pintzas, A.2
-
8
-
-
33749316418
-
The epidermal growth factor receptor pathway: a model for targeted therapy
-
PID: 17000658, COI: 1:CAS:528:DC%2BD28XpvFShs74%3D
-
Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5268-5272
-
-
Scaltriti, M.1
Baselga, J.2
-
9
-
-
33748063941
-
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
-
PID: 16854453, COI: 1:CAS:528:DC%2BD1cXhs12lurs%3D
-
McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249–79.
-
(2006)
Adv Enzyme Regul
, vol.46
, pp. 249-279
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
-
10
-
-
21644473447
-
Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression
-
PID: 15702478, COI: 1:CAS:528:DC%2BD2MXlvFCrsL0%3D
-
Calistri D, Rengucci C, Seymour I, et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol. 2005;204:484–8.
-
(2005)
J Cell Physiol
, vol.204
, pp. 484-488
-
-
Calistri, D.1
Rengucci, C.2
Seymour, I.3
-
11
-
-
1342299898
-
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
-
PID: 14688025
-
Fransén K, Klintenäs M, Osterström A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527–33.
-
(2004)
Carcinogenesis
, vol.25
, pp. 527-533
-
-
Fransén, K.1
Klintenäs, M.2
Osterström, A.3
-
12
-
-
77953629804
-
Molecular markers in the treatment of metastatic colorectal cancer
-
PID: 20526105, COI: 1:CAS:528:DC%2BC3cXovV2rtLw%3D
-
Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010;16(3):262–72.
-
(2010)
Cancer J
, vol.16
, Issue.3
, pp. 262-272
-
-
Wilson, P.M.1
Labonte, M.J.2
Lenz, H.J.3
-
13
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
PID: 19001320
-
Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–12.
-
(2008)
J Clin Oncol
, vol.26
, Issue.35
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
-
14
-
-
78649739337
-
Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status
-
Bokemeyer C, Kohne C, Rougier P, et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol. 2010;28:15s.
-
(2010)
J Clin Oncol
, vol.28
, pp. 15s
-
-
Bokemeyer, C.1
Kohne, C.2
Rougier, P.3
-
15
-
-
11144358645
-
High frequency of mutations of the PIK3CA gene in human cancers
-
PID: 15016963, COI: 1:CAS:528:DC%2BD2cXjsVGmsbk%3D
-
Samuels Y, Wang ZH, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
-
(2004)
Science
, vol.304
, pp. 554
-
-
Samuels, Y.1
Wang, Z.H.2
Bardelli, A.3
-
16
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
-
PID: 19223544, COI: 1:CAS:528:DC%2BD1MXisFSrt7Y%3D
-
Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–7.
-
(2009)
Cancer Res
, vol.69
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
Molinari, F.3
-
17
-
-
79960927451
-
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
-
PID: 21829508, COI: 1:CAS:528:DC%2BC3MXhtVyksLzO
-
Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011;6:e22769. doi:10.1371/journal.pone.0022769.
-
(2011)
PLoS One
, vol.6
, pp. e22769
-
-
Janku, F.1
Lee, J.J.2
Tsimberidou, A.M.3
-
18
-
-
34047248571
-
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
-
PID: 17363584, COI: 1:CAS:528:DC%2BD2sXivV2ns7w%3D
-
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–8.
-
(2007)
Cancer Res
, vol.67
, pp. 2643-2648
-
-
Benvenuti, S.1
Sartore-Bianchi, A.2
Di Nicolantonio, F.3
-
19
-
-
84939929465
-
-
Douillard J, Siena S, Cassidy J et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer. 2009;7S(3):6. Abstract LBA10.
-
Douillard J, Siena S, Cassidy J et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer. 2009;7S(3):6. Abstract LBA10.
-
-
-
-
20
-
-
84863940087
-
Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma
-
PID: 22427190, COI: 1:CAS:528:DC%2BC2cXhsVOhu7g%3D
-
Bagadi SB, Sanghvi M, Nair SB, et al. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 2012;27:27–33.
-
(2012)
Int J Biol Markers
, vol.27
, pp. 27-33
-
-
Bagadi, S.B.1
Sanghvi, M.2
Nair, S.B.3
-
21
-
-
84878244603
-
KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort
-
PID: 23729268
-
Patil H, Korde R, Kapat A. KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. Med Oncol. 2013;30:617.
-
(2013)
Med Oncol
, vol.30
, pp. 617
-
-
Patil, H.1
Korde, R.2
Kapat, A.3
-
22
-
-
84875730328
-
Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population
-
Sinha R, Hussain S, Mehrotra R, et al. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One. 2013;. doi:10.1371/journal.pone.0060142.
-
(2013)
PLoS One
-
-
Sinha, R.1
Hussain, S.2
Mehrotra, R.3
-
23
-
-
84878707082
-
Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians
-
PID: 23526092, COI: 1:CAS:528:DC%2BC3sXos1yksr4%3D
-
Malhotra P, Anwar M, Nanda N, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol. 2013;34:1901–11.
-
(2013)
Tumour Biol
, vol.34
, pp. 1901-1911
-
-
Malhotra, P.1
Anwar, M.2
Nanda, N.3
-
24
-
-
51449101924
-
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
-
PID: 19238633, COI: 1:CAS:528:DC%2BD1cXhtV2jurrP
-
Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923–9.
-
(2008)
Br J Cancer
, vol.99
, pp. 923-929
-
-
Kalikaki, A.1
Koutsopoulos, A.2
Trypaki, M.3
-
25
-
-
33644586429
-
Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)
-
PID: 16452550, COI: 1:CAS:528:DC%2BD28XitlGltL4%3D
-
Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006;154:341–8.
-
(2006)
Eur J Endocrinol
, vol.154
, pp. 341-348
-
-
Sapio, M.R.1
Posca, D.2
Troncone, G.3
-
26
-
-
84860617477
-
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer
-
PID: 22586484, COI: 1:CAS:528:DC%2BC38Xns1ajtb4%3D
-
Mao C, Zhou J, Yang Z, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One. 2012;7:e36653. doi:10.1371/journal.pone.0036653.
-
(2012)
PLoS One
, vol.7
, pp. e36653
-
-
Mao, C.1
Zhou, J.2
Yang, Z.3
-
27
-
-
77950819136
-
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
-
PID: 20398348
-
Barbi S, Cataldo I, De Manzoni G, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res. 2010;29:32. doi:10.1186/1756-9966-29-32.
-
(2010)
J Exp Clin Cancer Res
, vol.29
, pp. 32
-
-
Barbi, S.1
Cataldo, I.2
De Manzoni, G.3
-
28
-
-
16644393213
-
The PIK3CA gene is mutated with high frequency in human breast cancers
-
PID: 15254419, COI: 1:CAS:528:DC%2BD2MXhslKrtbw%3D
-
Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3:772–5.
-
(2004)
Cancer Biol Ther
, vol.3
, pp. 772-775
-
-
Bachman, K.E.1
Argani, P.2
Samuels, Y.3
-
29
-
-
84939929467
-
-
World Health Organisation Cancer Incidence in Five Continents. Lyon: The World Health Organisation and The International Agency for Research on Cancer; 2002.
-
World Health Organisation Cancer Incidence in Five Continents. Lyon: The World Health Organisation and The International Agency for Research on Cancer; 2002.
-
-
-
-
30
-
-
0027223762
-
Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study
-
PID: 8474513, COI: 1:STN:280:DyaK3s3jtlOhtQ%3D%3D
-
Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.
-
(1993)
N Engl J Med
, vol.328
, pp. 1365-1371
-
-
Mandel, J.S.1
Bond, J.H.2
Church, T.R.3
-
31
-
-
0028835677
-
Cancer Statistics, 1995
-
PID: 7528632, COI: 1:STN:280:DyaK2M7gtlektA%3D%3D
-
Wingo PA, Tong T, Bolden S. Cancer Statistics, 1995. CA Cancer J Clin. 1995;45:8–30.
-
(1995)
CA Cancer J Clin
, vol.45
, pp. 8-30
-
-
Wingo, P.A.1
Tong, T.2
Bolden, S.3
-
32
-
-
33646228635
-
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
-
PID: 16618717
-
Liévre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5.
-
(2006)
Cancer Res
, vol.66
, pp. 3992-3995
-
-
Liévre, A.1
Bachet, J.B.2
Le Corre, D.3
-
33
-
-
44449090596
-
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
-
PID: 18621636, COI: 1:CAS:528:DC%2BD1cXnvVCqt78%3D
-
Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008;7:184–90.
-
(2008)
Clin Colorectal Cancer
, vol.7
, pp. 184-190
-
-
Freeman, D.J.1
Juan, T.2
Reiner, M.3
-
34
-
-
77955604846
-
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
-
PID: 20049837, COI: 1:CAS:528:DC%2BC3cXpt1Ohsbs%3D
-
Perkins G, Lièvre A, Ramacci C, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer. 2010;127:1321–31.
-
(2010)
Int J Cancer
, vol.127
, pp. 1321-1331
-
-
Perkins, G.1
Lièvre, A.2
Ramacci, C.3
-
35
-
-
22144452507
-
The prevalence of PIK3CA mutations in gastric and colon cancer
-
PID: 15994075, COI: 1:CAS:528:DC%2BD2MXmsVCmu7s%3D
-
Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41:1649–54.
-
(2005)
Eur J Cancer
, vol.41
, pp. 1649-1654
-
-
Velho, S.1
Oliveira, C.2
Ferreira, A.3
-
36
-
-
42149083899
-
Mutations in the RASMAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
-
PID: 18224685, COI: 1:CAS:528:DC%2BD1cXkslynsb4%3D
-
Barault L, Veyrie N, Jooste V, et al. Mutations in the RASMAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008;122:2255–9.
-
(2008)
Int J Cancer
, vol.122
, pp. 2255-2259
-
-
Barault, L.1
Veyrie, N.2
Jooste, V.3
-
37
-
-
46349092797
-
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
-
PID: 18577988, COI: 1:CAS:528:DC%2BD1cXnvFeru7Y%3D
-
Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83–9.
-
(2008)
Br J Cancer
, vol.99
, pp. 83-89
-
-
Cappuzzo, F.1
Varella-Garcia, M.2
Finocchiaro, G.3
-
38
-
-
48649092117
-
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
-
PID: 18628094, COI: 1:CAS:528:DC%2BD1cXhtVegtbnM
-
Simi L, Pratesi N, Vignoli M, et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol. 2008;130:247–53.
-
(2008)
Am J Clin Pathol
, vol.130
, pp. 247-253
-
-
Simi, L.1
Pratesi, N.2
Vignoli, M.3
-
39
-
-
53149097362
-
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
-
PID: 18782444
-
Velho S, Moutinho C, Cirnes L, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer. 2008;8:255.
-
(2008)
BMC Cancer
, vol.8
, pp. 255
-
-
Velho, S.1
Moutinho, C.2
Cirnes, L.3
-
40
-
-
59049089201
-
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
-
PID: 18669866, COI: 1:STN:280:DC%2BD1M%2Fns1yktw%3D%3D
-
Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20:84–90.
-
(2009)
Ann Oncol
, vol.20
, pp. 84-90
-
-
Perrone, F.1
Lampis, A.2
Orsenigo, M.3
Di Bartolomeo, M.4
-
41
-
-
63049111794
-
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
-
PID: 19237633, COI: 1:CAS:528:DC%2BD1MXksF2hsL4%3D
-
Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009;27:1477–84.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1477-1484
-
-
Ogino, S.1
Nosho, K.2
Kirkner, G.J.3
-
42
-
-
68149165771
-
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
-
PID: 19603024, COI: 1:CAS:528:DC%2BD1MXpsVKmsr4%3D
-
Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465–72.
-
(2009)
Br J Cancer
, vol.101
, pp. 465-472
-
-
Souglakos, J.1
Philips, J.2
Wang, R.3
-
43
-
-
79952851688
-
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers
-
PID: 21425139, COI: 1:CAS:528:DC%2BC3MXkslWiu7s%3D
-
Baba Y, Nosho K, Shima K, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011;117:1399–408.
-
(2011)
Cancer
, vol.117
, pp. 1399-1408
-
-
Baba, Y.1
Nosho, K.2
Shima, K.3
-
44
-
-
76049098292
-
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases
-
PID: 20103678, COI: 1:CAS:528:DC%2BC3cXhs1aqsr4%3D
-
Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790–9.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 790-799
-
-
Baldus, S.E.1
Schaefer, K.L.2
Engers, R.3
-
45
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
-
PID: 20619739
-
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
-
46
-
-
77952536391
-
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes
-
PID: 20098682
-
Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One. 2010;5:e8802. doi:10.1371/journal.pone.0008802.
-
(2010)
PLoS One
, vol.5
, pp. e8802
-
-
Lurkin, I.1
Stoehr, R.2
Hurst, C.D.3
-
47
-
-
77955288855
-
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
-
PID: 20664172
-
Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120:2858–66.
-
(2010)
J Clin Invest
, vol.120
, pp. 2858-2866
-
-
Di Nicolantonio, F.1
Arena, S.2
Tabernero, J.3
-
48
-
-
79251633445
-
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients
-
PID: 21283802, COI: 1:CAS:528:DC%2BC3MXht1Ogsb8%3D
-
Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011;6:e15980. doi:10.1371/journal.pone.0015980.
-
(2011)
PLoS One
, vol.6
, pp. e15980
-
-
Saridaki, Z.1
Tzardi, M.2
Papadaki, C.3
-
49
-
-
79851496674
-
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer
-
PID: 21273607, COI: 1:CAS:528:DC%2BC3MXisVams78%3D
-
Wong NS, Fernando NH, Nixon AB, et al. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res. 2011;31:255–61.
-
(2011)
Anticancer Res
, vol.31
, pp. 255-261
-
-
Wong, N.S.1
Fernando, N.H.2
Nixon, A.B.3
-
50
-
-
84867817838
-
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
-
PID: 23094721, COI: 1:CAS:528:DC%2BC38Xhs1Whsr3K
-
Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–606.
-
(2012)
N Engl J Med
, vol.367
, pp. 1596-1606
-
-
Liao, X.1
Lochhead, P.2
Nishihara, R.3
-
51
-
-
84865438886
-
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
-
PID: 22931052, COI: 1:CAS:528:DC%2BC38XhvVShsr7N
-
Palomba G, Colombino M, Contu A, et al. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med. 2012;10:178.
-
(2012)
J Transl Med
, vol.10
, pp. 178
-
-
Palomba, G.1
Colombino, M.2
Contu, A.3
-
52
-
-
84872846788
-
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients
-
PID: 23125007, COI: 1:CAS:528:DC%2BC2cXhsVOhurk%3D
-
Bozzao C, Varvara D, Piglionica M, et al. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. Int J Biol Markers. 2012;27:e366–74.
-
(2012)
Int J Biol Markers
, vol.27
, pp. e366-e374
-
-
Bozzao, C.1
Varvara, D.2
Piglionica, M.3
-
53
-
-
84875483113
-
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
-
PID: 23548132, COI: 1:CAS:528:DC%2BC3sXotVKisb4%3D
-
Guedes JG, Veiga I, Rocha P, et al. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer. 2013;13:169.
-
(2013)
BMC Cancer
, vol.13
, pp. 169
-
-
Guedes, J.G.1
Veiga, I.2
Rocha, P.3
-
54
-
-
84885672295
-
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
-
PID: 23934607, COI: 1:CAS:528:DC%2BC3sXht12isrnO
-
Neumann J, Wehweck L, Maatz S, et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch. 2013;463:509–23.
-
(2013)
Virchows Arch
, vol.463
, pp. 509-523
-
-
Neumann, J.1
Wehweck, L.2
Maatz, S.3
-
55
-
-
84876711354
-
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
-
PID: 23617638, COI: 1:CAS:528:DC%2BC3sXnvFWqtb0%3D
-
Derbel O, Wang Q, Desseigne F, et al. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. BMC Cancer. 2013;13:200.
-
(2013)
BMC Cancer
, vol.13
, pp. 200
-
-
Derbel, O.1
Wang, Q.2
Desseigne, F.3
-
56
-
-
84881255039
-
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab
-
PID: 23741067, COI: 1:CAS:528:DC%2BC3sXht1amt77F
-
Smith CG, Fisher D, Claes B, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res. 2013;19:4104–13.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4104-4113
-
-
Smith, C.G.1
Fisher, D.2
Claes, B.3
-
57
-
-
84881276548
-
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients
-
PID: 23943423
-
Yanus GA, Belyaeva AV, Ivantsov AO, et al. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. Med Oncol. 2013;30:686.
-
(2013)
Med Oncol
, vol.30
, pp. 686
-
-
Yanus, G.A.1
Belyaeva, A.V.2
Ivantsov, A.O.3
-
58
-
-
84879001702
-
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival
-
PID: 23785428, COI: 1:CAS:528:DC%2BC3sXhtVams73O
-
Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One. 2013;8:e65479. doi:10.1371/journal.pone.0065479.
-
(2013)
PLoS One
, vol.8
, pp. e65479
-
-
Rosty, C.1
Young, J.P.2
Walsh, M.D.3
-
59
-
-
84905537957
-
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset
-
PID: 21103049
-
Berg M, Danielsen SA, Ahlquist T, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One. 2010;5:e13978. doi:10.1371/journal.pone.0013978.
-
(2010)
PLoS One
, vol.5
, pp. e13978
-
-
Berg, M.1
Danielsen, S.A.2
Ahlquist, T.3
-
60
-
-
77956610320
-
Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers
-
COI: 1:CAS:528:DC%2BC3cXhtFyqtbfE
-
Liao W, Liao Y, Zhou JX, et al. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Anat Rec. 2010;293:1506–11.
-
(2010)
Anat Rec
, vol.293
, pp. 1506-1511
-
-
Liao, W.1
Liao, Y.2
Zhou, J.X.3
-
61
-
-
82655177985
-
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
-
PID: 22070922, COI: 1:CAS:528:DC%2BC3MXhsFygtb7M
-
Kwon MJ, Lee SE, Kang SY, et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract. 2011;207:762–8.
-
(2011)
Pathol Res Pract
, vol.207
, pp. 762-768
-
-
Kwon, M.J.1
Lee, S.E.2
Kang, S.Y.3
-
62
-
-
79551578831
-
Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis
-
PID: 21174064
-
Aoyagi H, Iida S, Uetake H, et al. Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. Oncol Rep. 2011;25:789–94.
-
(2011)
Oncol Rep
, vol.25
, pp. 789-794
-
-
Aoyagi, H.1
Iida, S.2
Uetake, H.3
-
63
-
-
84864390143
-
Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population
-
PID: 22579930, COI: 1:CAS:528:DC%2BC38XotVeltLY%3D
-
Hsieh LL, Er TK, Chen CC, et al. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta. 2012;413:1605–11.
-
(2012)
Clin Chim Acta
, vol.413
, pp. 1605-1611
-
-
Hsieh, L.L.1
Er, T.K.2
Chen, C.C.3
-
64
-
-
84867497326
-
Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma
-
PID: 23157825, COI: 1:CAS:528:DC%2BC3sXmt1ejsrY%3D
-
Ling Y, Ying JM, Qiu T, et al. Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi. 2012;41:590–4.
-
(2012)
Zhonghua Bing Li Xue Za Zhi
, vol.41
, pp. 590-594
-
-
Ling, Y.1
Ying, J.M.2
Qiu, T.3
-
65
-
-
84884957016
-
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
-
PID: 24006859
-
Bando H, Yoshino T, Shinozaki E, et al. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer. 2013;13:405. doi:10.1186/1471-2407-13-405.
-
(2013)
BMC Cancer
, vol.13
, pp. 405
-
-
Bando, H.1
Yoshino, T.2
Shinozaki, E.3
-
66
-
-
84884720425
-
Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia
-
PID: 23992303, COI: 1:CAS:528:DC%2BC3sXhsFOgsrbJ
-
Yip WK, Choo CW, Leong VCS, et al. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS. 2013;121:954–66.
-
(2013)
APMIS
, vol.121
, pp. 954-966
-
-
Yip, W.K.1
Choo, C.W.2
Leong, V.C.S.3
-
67
-
-
84891489355
-
Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer
-
PID: 23188063, COI: 1:CAS:528:DC%2BC3sXhvFymsL7O
-
Nakanishi R, Harada J, Tuul M, et al. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol. 2013;18:1042–8.
-
(2013)
Int J Clin Oncol
, vol.18
, pp. 1042-1048
-
-
Nakanishi, R.1
Harada, J.2
Tuul, M.3
-
68
-
-
84882648383
-
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
-
PID: 22638623, COI: 1:CAS:528:DC%2BC3sXhtlWgurrL
-
Soeda H, Shimodaira H, Watanabe M, et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol. 2013;18:670–7.
-
(2013)
Int J Clin Oncol
, vol.18
, pp. 670-677
-
-
Soeda, H.1
Shimodaira, H.2
Watanabe, M.3
-
69
-
-
79952392909
-
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
-
PID: 21305640, COI: 1:CAS:528:DC%2BC3MXivVGjs74%3D
-
Vaughn C, Zobell S, Furtado L, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50:307–12.
-
(2011)
Genes Chromosom Cancer
, vol.50
, pp. 307-312
-
-
Vaughn, C.1
Zobell, S.2
Furtado, L.3
-
70
-
-
75549090214
-
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
-
PID: 19679400, COI: 1:CAS:528:DC%2BC3cXhs1Kku70%3D
-
Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858–62.
-
(2009)
Pathol Res Pract
, vol.205
, pp. 858-862
-
-
Neumann, J.1
Zeindl-Eberhart, E.2
Kirchner, T.3
-
71
-
-
79954490871
-
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer
-
PID: 21424126, COI: 1:CAS:528:DC%2BC3MXnsVWhtLY%3D
-
Li HT, Lu YY, An YX, et al. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep. 2011;25:1691–7.
-
(2011)
Oncol Rep
, vol.25
, pp. 1691-1697
-
-
Li, H.T.1
Lu, Y.Y.2
An, Y.X.3
-
72
-
-
78649988884
-
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
-
PID: 21139621
-
Di Fiore F, Sesboue R, Michel P, et al. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer. 2010;103:1765–72.
-
(2010)
Br J Cancer
, vol.103
, pp. 1765-1772
-
-
Di Fiore, F.1
Sesboue, R.2
Michel, P.3
-
73
-
-
77954215850
-
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
-
PID: 20413299, COI: 1:CAS:528:DC%2BC3cXosVKjsbw%3D
-
Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer. 2010;46:1997–2009.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1997-2009
-
-
Tol, J.1
Dijkstra, J.R.2
Klomp, M.3
-
74
-
-
70349939382
-
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
-
PID: 19738166, COI: 1:CAS:528:DC%2BD1MXht1Ojt73I
-
Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308–24.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 1308-1324
-
-
Siena, S.1
Sartore-Bianchi, A.2
Di Nicolantonio, F.3
-
75
-
-
79953683140
-
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors
-
PID: 21473780, COI: 1:CAS:528:DC%2BC3MXltV2nu7Y%3D
-
Naguib A, Cooke JC, Happerfield L, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer. 2011;11:123.
-
(2011)
BMC Cancer
, vol.11
, pp. 123
-
-
Naguib, A.1
Cooke, J.C.2
Happerfield, L.3
-
76
-
-
84860634396
-
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
-
PID: 22039088, COI: 1:STN:280:DC%2BC38zmvFyitA%3D%3D
-
Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012;23:1518–25.
-
(2012)
Ann Oncol
, vol.23
, pp. 1518-1525
-
-
Mao, C.1
Yang, Z.Y.2
Hu, X.F.3
-
77
-
-
21144457217
-
Functional analysis of PIK3CA gene mutations in human colorectal cancer
-
PID: 15930273, COI: 1:CAS:528:DC%2BD2MXks1Oht7c%3D
-
Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65:4562–7.
-
(2005)
Cancer Res
, vol.65
, pp. 4562-4567
-
-
Ikenoue, T.1
Kanai, F.2
Hikiba, Y.3
-
78
-
-
34447503808
-
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit
-
PID: 17626883, COI: 1:CAS:528:DC%2BD2sXnsFaqtrg%3D
-
Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007;317:239–42.
-
(2007)
Science
, vol.317
, pp. 239-242
-
-
Miled, N.1
Yan, Y.2
Hon, W.C.3
-
79
-
-
34250835879
-
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model
-
PID: 17575153, COI: 1:CAS:528:DC%2BD2sXmsFCqtro%3D
-
Guo XN, Rajput A, Rose R, et al. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res. 2007;67:5851–8.
-
(2007)
Cancer Res
, vol.67
, pp. 5851-5858
-
-
Guo, X.N.1
Rajput, A.2
Rose, R.3
-
80
-
-
34248369435
-
Rare cancer-specific mutations in PIK3CA show gain of function
-
PID: 17376864, COI: 1:CAS:528:DC%2BD2sXkt1emtb8%3D
-
Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci. 2007;104:5569–74.
-
(2007)
Proc Natl Acad Sci
, vol.104
, pp. 5569-5574
-
-
Gymnopoulos, M.1
Elsliger, M.A.2
Vogt, P.K.3
-
81
-
-
40649096375
-
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
-
PID: 18268322, COI: 1:CAS:528:DC%2BD1cXis1yjtr0%3D
-
Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci. 2008;105:2652–7.
-
(2008)
Proc Natl Acad Sci
, vol.105
, pp. 2652-2657
-
-
Zhao, L.1
Vogt, P.K.2
-
82
-
-
14144252004
-
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
-
PID: 15647370, COI: 1:CAS:528:DC%2BD2MXis1Cqsb0%3D
-
Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci. 2005;102:802–7.
-
(2005)
Proc Natl Acad Sci
, vol.102
, pp. 802-807
-
-
Kang, S.1
Bader, A.G.2
Vogt, P.K.3
|